Apogee Therapeutics (APGE) Insider Trading & Ownership $34.55 +0.60 (+1.77%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$34.65 +0.10 (+0.29%) As of 02/21/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Apogee Therapeutics (NASDAQ:APGE) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage36.10%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$990,800.00Number OfInsiders Selling(Last 12 Months)3Amount OfInsider Selling(Last 12 Months)$12.03 M Get APGE Insider Trade Alerts Want to know when executives and insiders are buying or selling Apogee Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address APGE Insider Buying and Selling by Quarter Apogee Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/5/2025Carl DambkowskiInsiderSell3,520$40.69$143,228.80 2/5/2025Michael Thomas HendersonCEOSell15,000$40.58$608,700.00 1/8/2025Michael Thomas HendersonCEOSell15,000$48.85$732,750.00 1/2/2025Carl DambkowskiInsiderSell4,085$46.94$191,749.90 12/12/2024Mark C MckennaDirectorBuy20,000$49.54$990,800.00 12/11/2024Carl DambkowskiInsiderSell4,540$48.76$221,370.40 12/4/2024Carl DambkowskiInsiderSell6,665$46.07$307,056.55 12/4/2024Michael Thomas HendersonCEOSell15,000$46.58$698,700.00 11/6/2024Carl DambkowskiInsiderSell6,665$59.12$394,034.80 11/6/2024Michael Thomas HendersonCEOSell15,000$59.22$888,300.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 10/2/2024Carl DambkowskiInsiderSell6,665$56.26$374,972.90 10/2/2024Michael Thomas HendersonCEOSell40,000$56.23$2,249,200.00 9/4/2024Carl DambkowskiInsiderSell6,665$47.56$316,987.40 9/4/2024Michael Thomas HendersonCEOSell40,000$47.62$1,904,800.00 8/23/2024Jane HendersonCFOSell6,000$48.26$289,560.00 8/7/2024Carl DambkowskiInsiderSell7,335$40.67$298,314.45 8/7/2024Michael Thomas HendersonCEOSell40,000$40.62$1,624,800.00 7/5/2024Michael Thomas HendersonCEOSell15,000$37.26$558,900.00 7/3/2024Carl DambkowskiInsiderSell5,995$37.60$225,412.00 (Data available from 1/1/2013 forward) APGE Insider Trading Activity - Frequently Asked Questions Who is on Apogee Therapeutics's Insider Roster? The list of insiders at Apogee Therapeutics includes Carl Dambkowski, Jane Henderson, Mark C Mckenna, Michael Thomas Henderson, and Nimish P Shah. Learn more on insiders at APGE. What percentage of Apogee Therapeutics stock is owned by insiders? 36.10% of Apogee Therapeutics stock is owned by insiders. Learn more on APGE's insider holdings. Which Apogee Therapeutics insiders have been buying company stock? The following insiders have purchased APGE shares in the last 24 months: Mark C Mckenna ($990,800.00), and Nimish P Shah ($29,750,000.00). How much insider buying is happening at Apogee Therapeutics? Insiders have purchased a total of 1,770,000 APGE shares in the last 24 months for a total of $30,740,800.00 bought. Which Apogee Therapeutics insiders have been selling company stock? The following insiders have sold APGE shares in the last 24 months: Carl Dambkowski ($2,473,127.20), Jane Henderson ($289,560.00), and Michael Thomas Henderson ($9,266,150.00). How much insider selling is happening at Apogee Therapeutics? Insiders have sold a total of 253,135 Apogee Therapeutics shares in the last 24 months for a total of $12,028,837.20 sold. Apogee Therapeutics Key ExecutivesDr. Michael Thomas Henderson M.D. (Age 34)CEO & Director Compensation: $1.17M6 recent tradesMs. Jane Pritchett V. Henderson (Age 58)Chief Financial Officer Compensation: $843.64kDr. Carl Linden Dambkowski M.D. (Age 38)Chief Medical Officer Compensation: $870.83kMs. Noel KurdiVice President of Investor RelationsMr. Matthew Batters J.D. (Age 48)Chief Legal Officer & Corporate Secretary Ms. Emily CoxVP & Head of PeopleDr. Rebecca Dabora Ph.D. (Age 64)Chief Development Officer Ms. Wendy Aspden-CurranSenior Vice President of Clinical OperationsDr. Drew Badger Ph.D.Senior VP and Head of Regulatory Affairs & ToxicologyMs. Monica Forbes (Age 48)Senior Vice President of Finance More Insider Trading Tools from MarketBeat Related Companies AXSM Insider Trading BPMC Insider Trading ELAN Insider Trading LNTH Insider Trading NUVL Insider Trading CYTK Insider Trading VRNA Insider Trading GRFS Insider Trading TGTX Insider Trading KRYS Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying This page (NASDAQ:APGE) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APGE Stock Alerts